UI 034
Alternative Names: UI-034Latest Information Update: 28 Sep 2025
At a glance
- Originator Korea United Pharm Inc
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Asthma in South Korea (Inhalation, Powder)
- 27 Aug 2021 UI 034 is available for licensing as of 27 Aug 2021. https://www.kup.co.kr/research/innovation_main.htm
- 27 Aug 2021 Preclinical trials in Asthma in South Korea (Inhalation), prior to August 2021 (Korea United Pharm pipeline, August 2021)